• Astellas Bets On Gene Therapy With $3B Audentes Acquisition Offer

    9 days ago - By Xconomy

    Japanese drug giant Astellas Pharma announced late Monday it has agreed to buy Audentes Therapeutics, which is developing gene therapies for rare neuromuscular diseases. It's an all-cash deal worth $3 billion, with the Astellas offer of $60 per share representing a 110 percent premium to Audentes' share price of $28.61 apiece at market close Monday. The agreement is the latest big bet by a major pharmaceutical company on gene therapy, which aims to provide long-lasting, if not permanent, disease treatments. San Francisco-based Audentes' lead drug candidate, AT132, is a clinical-stage...
    Read more ...

     

  • Astellas inks $3B Audentes buyout to expand in gene therapy

    Astellas inks $3B Audentes buyout to expand in gene therapy

    9 days ago - By Fierce Biotech

    Astellas Pharma is set to buy Audentes Therapeutics for $3 billion. The deal will enable Astellas to set up a new genetic regulation unit spearheaded by a neuromuscular disease gene therapy that is set to be submitted for approval next year.
    Read more ...